Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 02 2019
Historique:
received: 29 06 2018
revised: 10 10 2018
accepted: 19 11 2018
pubmed: 30 11 2018
medline: 21 4 2020
entrez: 30 11 2018
Statut: ppublish

Résumé

Mutations in Plasma samples collected from panitumumab-treated patients in the ASPECCT study at baseline and safety follow-up (SFU) were analyzed by a next-generation sequencing-based approach for extended Overall, 261 patients in the panitumumab arm had evaluable plasma samples. Patients with a higher When mutations in

Identifiants

pubmed: 30487126
pii: 1078-0432.CCR-18-2072
doi: 10.1158/1078-0432.CCR-18-2072
doi:

Substances chimiques

Biomarkers, Tumor 0
Cell-Free Nucleic Acids 0
KRAS protein, human 0
Mutant Proteins 0
Panitumumab 6A901E312A
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1216-1225

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Marc Peeters (M)

Antwerp University Hospital, Edegem, Belgium.

Timothy Price (T)

Antwerp University Hospital, Edegem, Belgium.
The Queen Elizabeth Hospital and University of Adelaide, Woodville, Australia.

Michael Boedigheimer (M)

Amgen Inc., Thousand Oaks, California.

Tae Won Kim (TW)

Asan Medical Center, University of Ulsan, Seoul, South Korea.

Paul Ruff (P)

University of Witwatersrand MRC Common Epithelial Cancers Research Centre, Johannesburg, South Africa.

Peter Gibbs (P)

The Western Hospital, Melbourne, Australia.

Anne Thomas (A)

University of Leicester, Leicester, United Kingdom.

Gaston Demonty (G)

Amgen (Europe) GmbH, Zug, Switzerland.

Kristina Hool (K)

Amgen Inc., Thousand Oaks, California.

Agnes Ang (A)

Amgen Inc., Thousand Oaks, California. agnesa@amgen.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH